Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Accumulated Expenses (2023 - 2025)

Indivior Pharmaceuticals has reported Other Accumulated Expenses over the past 3 years, most recently at $106.0 million for Q3 2025.

  • Quarterly results put Other Accumulated Expenses at $106.0 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $106.0 million (changed N/A YoY), and the annual figure for FY2024 was $99.0 million, down 79.88%.
  • Other Accumulated Expenses for Q3 2025 was $106.0 million at Indivior Pharmaceuticals, up from $105.0 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for INDV hit a ceiling of $492.0 million in Q4 2023 and a floor of $99.0 million in Q4 2024.
  • Median Other Accumulated Expenses over the past 3 years was $105.0 million (2025), compared with a mean of $181.4 million.
  • Peak annual rise in Other Accumulated Expenses hit 79.88% in 2024, while the deepest fall reached 79.88% in 2024.
  • Indivior Pharmaceuticals' Other Accumulated Expenses stood at $492.0 million in 2023, then tumbled by 79.88% to $99.0 million in 2024, then grew by 7.07% to $106.0 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $106.0 million (Q3 2025), $105.0 million (Q2 2025), and $105.0 million (Q1 2025) per Business Quant data.